Stephen David Prior - Nov 4, 2024 Form 3 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role: Chief Strategy Officer
Signature: /s/ Lucy Day, Attorney-in-Fact for Stephen David Prior
Stock symbol: ANTX
Transactions as of: Nov 4, 2024
Transactions value $: $0
Form type: 3
Date filed: 11/5/2024, 04:49 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ANTX	Common Stock						25.2K	Nov 4, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ANTX	Stock Option (right to buy)							Nov 4, 2024	Common Stock	46K	$0.00	Direct	F2
holding	ANTX	Stock Option (right to buy)							Nov 4, 2024	Common Stock	29.2K	$0.00	Direct	F3
holding	ANTX	Stock Option (right to buy)							Nov 4, 2024	Common Stock	35K	$0.00	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes a balance of 17,500 Restricted Stock Units ("RSUs"). RSUs vest as follows: 1/16th of RSUs vest quarterly over four years from January 1, 2024 until fully vested on January 1, 2028, subject to the Reporting Person's continuous service as of such date.
F2	The shares subject to the option are exercisable and vest as follows: 1/4th of the shares vest and becomes exercisable on September 20, 2023. Thereafter, 1/48th of the shares vest and becomes exercisable monthly over the following three years until fully vested and exercisable on September 20, 2026, subject to the Reporting Person's continuous service as of such date.
F3	The shares subject to the option are exercisable and vest as follows: 1/48th of the shares vest and becomes exercisable monthly over four years from January 1, 2023 until fully vested and exercisable on January 1, 2027, subject to the Reporting Person's continuous service as of such date.
F4	The shares subject to the option shall continue to vest and become exercisable as originally approved through December 31, 2024. On January 1, 2025, 1/3 of the remaining unvested shares (rounded down to the nearest whole number of shares) shall vest and all remaining unvested shares shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.

Remarks:

Exhibits: Power of Attorney